An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

  • STATUS
    Recruiting
  • End date
    Apr 30, 2024
  • participants needed
    280
  • sponsor
    Astellas Pharma Global Development, Inc.
Updated on 29 October 2022

Summary

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR).

This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin.

Description

This study will consist of 3 periods: screening/baseline, treatment and follow-up.

Screening/baseline period will take place up to 28 days prior to the first dose of study treatment.

In the treatment period, starting at cycle 1, participants will receive enfortumab vedotin on days 1, 8, and 15 every 28-day cycle until one of the treatment discontinuation criteria are met. Disease assessment will be performed at screening/baseline and repeated every 8 weeks (56 days ± 7 days) from the first dose of study treatment throughout the study until the participant has radiologically confirmed disease progression, initiates a new subsequent anticancer therapy, dies, withdraws consent, is lost to follow-up or the study closes, whichever occurs first.

Participants who discontinue study treatment for reasons other than radiologically-confirmed disease progression by RECIST Version 1.1 will enter into a post treatment follow-up period and continue to receive imaging scans every 8 weeks (56 days ± 7 days) until the subject has radiologically confirmed disease progression, initiates a new anticancer therapy, dies, withdraws consent, is lost to follow-up or the study closes, whichever occurs first.

After 1 year on study treatment, the frequency of disease assessment will be reduced to every 12 weeks (84 days ± 7 days).

After radiologically-confirmed disease progression or initiation of subsequent anticancer therapy, whichever occurs first, participants will be contacted every 12 weeks in the long-term follow-up period for survival status until death, withdrawal of consent, lost to follow-up or study closure, whichever occurs first.

Details
Condition Locally Advanced or Metastatic Malignant Solid Tumors
Treatment Enfortumab vedotin
Clinical Study IdentifierNCT04225117
SponsorAstellas Pharma Global Development, Inc.
Last Modified on29 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject is considered an adult according to local regulation at the time of signing the informed consent form (ICF)
Subject has measurable disease by RECIST Version 1.1
Subject has accessible archival tumor tissue from either the primary tumor or a metastatic site, for which source and availability have been confirmed prior to study treatment. If no archival tumor tissue is available, the subject will have a biopsy to obtain tumor tissue prior to study treatment. If the subject is unable to undergo a biopsy due to safety concerns, enrollment into the study must be discussed with the medical monitor
Subject has ECOG performance status of 0 or 1
Subject has the following baseline laboratory data. If a subject has received a recent blood transfusion, the hematology tests must be obtained ≥ 28 days after any blood transfusion
absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L
platelet count ≥ 100 × 10^9/L
hemoglobin ≥ 9 g/dL
serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for subjects with Gilbert's disease
creatinine clearance (CrCl) ≥ 30 mL/min as estimated per institutional standards or as measured by 24-hour urine collection (glomerular filtration rate [GFR] can also be used instead of CrCl)
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
Subject agrees not to participate in another interventional study while receiving
Additional contraceptive requirements exist for male and female subjects
study treatment in the present study
Disease Specific Inclusion Criteria
Evidence of progression on or after the last regimen received
Locally advanced or metastatic disease that is not amenable to curative intent treatment
Cohort 1: HR+/HER2- breast cancer
Subject has evidence of radiographic progression on or after the last regimen received
Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen
Subject has histologically- or cytologically-confirmed HR+/HER2- (estrogen receptor [ER] positive and/or progesterone receptor [PR] positive, and HER2 negative) breast cancers and are not considered a candidate for further hormonal therapy. Subject will be considered HR+ if biopsies show ≥ 1% expression of ER or PR as per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment
Cohort 2: triple negative breast cancer (TNBC)
Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting
Subject has histologically- or cytologically-confirmed TNBC; defined as unequivocal TNBC histology (ER-negative/PR-negative/HER2-negative). This is defined by < 1% expression of ER and PR by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified) as per current ASCO/CAP guidelines
Subject has progressed, relapsed, or discontinued for toxicity during or after at
Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen
least 1 prior standard of care cytotoxic regimen in the incurable
Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed or discontinued treatment due to toxicity, or therapy is contraindicated for subject
unresectable locally advanced or metastatic setting, and has not received > 2
Cohort 3: squamous non-small cell lung cancer (NSCLC)
prior lines of cytotoxic therapy in the locally advanced or metastatic
Subject has histologically or cytologically-confirmed squamous NSCLC
setting. No limit applies to endocrine therapies. Poly(ADP-ribose) polymerases
Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology
(PARP) inhibitors do not count as a line of cytotoxic therapy
Subjects with known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity
Subject has progressed, relapsed, or discontinued for toxicity during or after receiving endocrine therapy or with hormonally-directed therapy with cyclin-dependent kinase (CDK) inhibitors. Prior therapy with CDK inhibitors is not required
Subject has evidence of radiographic progression on or after the last regimen received
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment
Cohort 4: non-squamous non-small cell lung cancer
Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting
Subject has histologically- or cytologically-confirmed non-squamous NSCLC
Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology
Subject has progressed, relapsed, or discontinued for toxicity during or after at
Subjects with known EGFR, ALK, ROS, BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity
least 1 prior standard of care cytotoxic regimen in the incurable
unresectable locally advanced or metastatic setting, and has not received > 2
prior lines of cytotoxic therapy in the locally advanced or metastatic
setting. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line
of cytotoxic therapy
Cohort 5: head and neck cancer
Subject has histologically- or cytologically-confirmed head and neck cancer
Subject has evidence of radiographic progression on or after the last regimen received
Subject has locally advanced or metastatic disease that is not amenable to curative
Subject has histologically- or cytologically-confirmed gastric, GEJ, or esophageal cancer
intent treatment
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting
Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion
Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen
Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression had occurred while on the initial therapy
Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1)
or anti-programmed cell death-ligand 1 (PD-L1) based on subject's tumor PD-1
or PD-L1 expression and local treatment guidelines and has progressed
relapsed, or discontinued treatment due to toxicity, or therapy is
contraindicated for subject
Subject has evidence of radiographic progression on or after the last regimen received
Subject has locally advanced or metastatic disease that is not amenable to curative
intent treatment
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting
Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion
Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen
Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression has occurred while on the initial therapy
Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's
tumor PD-1 or PD-L1 expression and local treatment guidelines and has
progressed, relapsed, or discontinued treatment due to toxicity, or therapy is
contraindicated for subject
Subject has evidence of radiographic progression on or after the last regimen received
Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 5
Subject has locally advanced or metastatic disease that is not amenable to curative
intent treatment
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting
Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months after completion
Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's
tumor PD-1 or PD-L1 expression and local treatment guidelines and has
progressed, relapsed, or discontinued treatment due to toxicity, or therapy is
contraindicated for subject
Cohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal
adenocarcinoma
Subject has evidence of radiographic progression on or after the last regimen received
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment
Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting
Neoadjuvant or adjuvant cytotoxic regimens will count as a prior regimen if relapsed or progressed ≤ 6 months after completion
Subject must have received a HER2 directed therapy if known to have HER2 positive
cancer
Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject

Exclusion Criteria

Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true
Baseline imaging scans show no evidence of new or enlarged brain metastasis
Subject does not have leptomeningeal disease
Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs)
Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed
Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted
Subject has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or active hepatitis C (e.g., hepatitis C virus [HCV] RNA [qualitative] is detected)
Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2)
Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug
Subject has major surgery within 4 weeks prior to first dose of study drug
Subject had radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug
Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells
Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated
Subject has any condition which makes the subject unsuitable for study participation
Subject has preexisting sensory or motor neuropathy Grade ≥ 2
CNS metastases have been clinically stable for ≥ 6 weeks prior to screening
If requiring steroid treatment for CNS metastases, the subject is on a stable dose ≤ 20 mg/day of prednisone or equivalent for ≥ 2 weeks
Subject has ongoing clinically significant toxicity (Grade 2 or higher with the
exception of alopecia) associated with prior treatment (including systemic
therapy, radiotherapy or surgery)
Subjects with ongoing ≥ Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (> 20 mg/day of prednisone or equivalent), are excluded. Subject with ≤ Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated)
Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) ≥ 8% or HbA1c between 7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note